Eli Lilly pulls Cymbalta journal ads following FDA letter

The FDA has called on Eli Lilly to stop running journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to reveal risks of the drug's use.
In a letter posted on the FDA's Web site last week, the agency said that ads are considered Cymbalta promotion even though their main panels don't mention the drug. Cymbalta, also used as an antidepressant, has risks including dementia if used with older antidepressants known as monoamine oxidase inhibitors.
It can also spur allergic reactions, the FDA said. A Lilly spokesperson told the Bloomberg news agency that the ads appeared in the fourth quarter of 2004 and first quarter of 2005 but won't appear again.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.